Skip to main content

Dactinomycin

ADVERTISEMENT
Identification
Molecular formula
C62H86N12O16
CAS number
50-76-0
IUPAC name
6-(1,3-dioxobenzo[de]isoquinolin-2-yl)hexanehydroxamic acid
State
State

At room temperature, Dactinomycin is in a solid state as a crystalline powder. It is stable under normal conditions but is sensitive to oxygen and light, which can cause it to degrade.

Melting point (Celsius)
253.00
Melting point (Kelvin)
526.00
Boiling point (Celsius)
410.00
Boiling point (Kelvin)
683.00
General information
Molecular weight
1255.44g/mol
Molar mass
1 255.4380g/mol
Density
1.3000g/cm3
Appearence

Dactinomycin appears as a yellow to orange-red crystalline powder. It is known for its use in chemotherapy and has a striking vibrant color typically associated with many anthracycline and chromophore-containing antibiotic compounds.

Comment on solubility

Solubility of 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)hexanehydroxamic acid

The solubility of 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)hexanehydroxamic acid, with the chemical formula C62H86N12O16, can be influenced by various factors due to its complex structure. Understanding the solubility behavior of this compound is crucial for its potential applications.

Key Factors Affecting Solubility:

  • Polarity: The presence of multiple functional groups may contribute to the polarity of the molecule, affecting its solubility in polar versus non-polar solvents.
  • Hydrogen Bonding: Hydroxamic acids can engage in hydrogen bonding, which may enhance solubility in water but could limit it in organic solvents.
  • Molecular Size: The large molecular weight and size of this compound can lead to decreased solubility due to steric hindrance.
  • Temperature: As with many compounds, increased temperature generally improves solubility, allowing for more effective dissolution in various solvents.

In conclusion, the solubility of this compound must be examined under specific conditions to determine its behavior in different solvents. As a guideline, “solubility is a dynamic characteristic that reflects a compound's interactions with the solvent environment.” Therefore, practical experimentation is encouraged for precise solubility data.

Interesting facts

Interesting Facts about 6-(1,3-Dioxobenzo[de]isoquinolin-2-yl)hexanehydroxamic Acid

This fascinating compound, known as 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)hexanehydroxamic acid, showcases the intricate relationship between organic chemistry and medicinal applications. Here are some engaging aspects of this compound:

  • Structural Complexity: The compound contains a unique 1,3-dioxobenzo moiety which forms a fused structure with the isoquinoline core. This complexity can lead to interesting interactions with biological systems.
  • Biodiversity: The isoquinoline skeleton is frequently found in various natural products and has been associated with a wide range of pharmacological activities, such as anti-cancer and anti-inflammatory properties.
  • Hydroxamic Acid Functionality: The presence of the hydroxamic acid group is notable. These compounds are known for their ability to inhibit certain enzymes, such as histone deacetylases (HDACs), which play a crucial role in gene regulation and cancer progression.
  • Potential Uses: Due to its structural features, there is significant interest in evaluating this compound for use in drug development, particularly in the context of cancer therapy and molecular targeting strategies.
  • Synthetic Route: The synthesis of this compound may involve multiple steps, reflecting the challenges and creativity involved in organic synthesis. Researchers can examine various synthetic pathways to optimize yields and increase efficiency.

As a conversation starter in the field of organic chemistry, 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)hexanehydroxamic acid serves to remind us of the ongoing quest to explore and develop novel compounds with therapeutic potential. The blend of unique structural features and promising biological activity exemplifies the excitement of modern medicinal chemistry.

Synonyms
scriptaid
287383-59-9
Scriptide
6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide
GCK 1026
GNF-PF-2024
6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide
Scriptide;GCK1026
1h-benz[de]isoquinoline-2(3h)-hexanamide, n-hydroxy-1,3-dioxo-
EJQ8CD8BSV
CHEMBL96051
SB-556629
N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide
N-Hydroxy-1,3-dioxo-1H-benz[de]isoquinoline-2(3H)-hexananmide
6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide
1H-BENZ(DE)ISOQUINOLINE-2(3H)-HEXANAMIDE, N-HYDROXY-1,3-DIOXO-
CGK-1026
MFCD00386477
UNII-EJQ8CD8BSV
Scriptaid(GCK1026)?
CBDivE_004422
Scriptaid, >=95%, solid
SCHEMBL780490
SCHEMBL780491
GTPL7505
CHEBI:92401
DTXSID70274458
GLXC-02821
HMS3269C11
HMS3413M06
HMS3653D06
HMS3677M06
BCP06506
EX-A1108
MLA38359
BDBM50328678
s8043
STL259803
AKOS000267387
CCG-208690
EG-0074
Scriptaid - CAS 287383-59-9
NCGC00159564-01
NCGC00159564-05
AC-35507
DA-33610
HY-15489
SW219824-1
SJ000016636
AB00075588-01
EN300-17995595
SR-01000398526
SR-01000398526-1
BRD-K22503835-001-03-7
BRD-K22503835-001-05-2
BRD-K22503835-001-11-0
BRD-K22503835-001-12-8
Q27088763
Z56773477
6-{2,4-dioxo-3-azatricyclo[7.3.1.0,5,13]trideca-1(13),5,7,9,11-pentaen-3-yl}-N-hydroxyhexanamide